GMAB vs NVO
Genmab A/S and Novo Nordisk A/S, side by side — 4 fiscal years reported in DKK, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | GMAB | NVO |
|---|---|---|
| Revenue | DKK 3.7B | DKK 309.1B |
| Net income | DKK 963.0M | DKK 102.4B |
| Gross margin | 93.6% | 81.0% |
| Net margin | 25.9% | 33.1% |
| Return on equity | — | — |
| Diluted EPS | DKK 15.37 | DKK 23.03 |
| Dividend / share | — | DKK 11.70 |
| Payout ratio | — | 50.5% |
| Free cash flow | DKK 1.1B | DKK 59.0B |
| Equity | — | — |
| Net debt / equity | — | — |
| Current ratio | 2.02× | 0.80× |
| Revenue CAGR 5y | — | 19.5% |
| Profit CAGR 5y | — | 19.4% |
NVO bills 83.1× the revenue of GMAB, and keeps more of each dollar of revenue as profit (33.1% against 25.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
4 years side by side
| Fiscal year | GMAB | NVO |
|---|---|---|
| FY2025 | DKK 3.7B | DKK 309.1B |
| FY2024 | DKK 3.1B | DKK 290.4B |
| FY2023 | DKK 2.4B | DKK 232.3B |
| FY2019 | DKK 5.4B | DKK 122.0B |
Net income by year
Bottom line
| Fiscal year | GMAB | NVO |
|---|---|---|
| FY2025 | DKK 963.0M | DKK 102.4B |
| FY2024 | DKK 7.8B | DKK 101.0B |
| FY2023 | DKK 4.4B | DKK 83.7B |
| FY2019 | DKK 2.2B | DKK 39.0B |
Advertisement
AdSense · Rectangle 336×280